Safeguard Jumps Into Life Science But Leaves Behind Early-Stage Risk
This article was originally published in Start Up
Executive Summary
With two major exits and a third pending, the traditionally high-tech-heavy investor's new strategy is paying off. Safeguard's lower appetite for risk in the life sciences means focusing on companies with existing or near-term revenues, cash flow, and net worth being built up, rather than dependence on a regulatory or clinical milestone as an inflection point. The firm also boasts an ability to bolster the management and operational capabilities of its young companies.